The boss of US pharmaceutical giant Eli Lilly says there is no looking back from Donald Trump's decision to impose sweeping ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Altria has an impressive streak of raising its dividend for 55 consecutive years. Eli Lilly's current streak only goes back ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

The stock's fall snapped a two-day winning streak.

Genomic medicine company Sangamo Therapeutics said it entered a license agreement with Eli Lilly, under which Lilly received rights to employ Sangamo's proprietary capsid, STAC-BBB, for up to five ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...